Management of IBD through improving intestinal barrier function by a novel Lactiplantibacillus plantarum C4 strain.

The novel Lactiplantibacillus plantarum C4 strain significantly decreased pro-inflammatory markers in DSS-induced colitis mice.

• Inflammation was assessed by measuring IL-6, IL-1β, and TNF-α levels in mice with dextran sodium sulphate (DSS)-induced colitis.
• The novel strain's anti-inflammatory effect was comparable to sulfasalazine treatment.
• The novel strain outperformed a commercial probiotic preparation in reducing inflammatory markers.

The novel Lactiplantibacillus plantarum C4 strain significantly reduced oxidative stress parameters in colitis mice.

• Oxidative stress was assessed by measuring Catalase and SOD (superoxide dismutase) activities and malondialdehyde (MDA) levels.
• The strain's effect on oxidative stress was comparable to sulfasalazine and superior to the commercial probiotic preparation.
• Reduction in MDA levels indicated decreased lipid peroxidation associated with colitis.

The novel Lactiplantibacillus plantarum C4 strain strengthened intestinal barrier function by increasing tight junction protein expression.

• Expression levels of claudin-1, occludin, and zonula occludens-1 (ZO-1) were measured in mice colon tissue and CaCo2 cell line.
• The strain increased expression of all three tight junction proteins in both in vivo (colon tissue) and in vitro (CaCo2 cell line) models.
• The effect on tight junction protein expression was comparable to sulfasalazine and superior to the commercial probiotic preparation.

Colitis was successfully induced in mice using dextran sodium sulphate (DSS) with multiple treatment comparison groups established.

• Study groups included a DSS-induced colitis group treated with the novel Lactiplantibacillus plantarum C4 strain, a group treated with a commercial probiotic preparation, and a group treated with sulfasalazine.
• The experimental model allowed direct comparison between the novel probiotic strain, a commercial probiotic, and a conventional IBD drug (sulfasalazine).
• Both in vivo (mouse colon tissue) and in vitro (CaCo2 cell line) models were used to assess intestinal barrier function.

The novel Lactiplantibacillus plantarum C4 strain demonstrated superior probiotic potential compared to a commercial probiotic preparation across all measured outcomes.

• The novel strain outperformed the commercial probiotic preparation in reducing IL-6, IL-1β, and TNF-α levels.
• The novel strain outperformed the commercial probiotic preparation in modulating oxidative stress markers (Catalase, SOD, MDA).
• The novel strain outperformed the commercial probiotic preparation in upregulating tight junction proteins claudin-1, occludin, and ZO-1.